Literature DB >> 19672627

Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers.

Yuichiro Mita1, Yukiko Yasuda, Akiko Sakai, Hiromasa Yamamoto, Shinichi Toyooka, Mehmet Gunduz, Shunsuke Tanabe, Yoshio Naomoto, Mamoru Ouchida, Kenji Shimizu.   

Abstract

PURPOSE: We investigated the association between incidence of various cancers and four single nucleotide polymorphisms (SNPs), two each in two protein tyrosine phosphatase (PTP) genes, PTPRJ and PTPN13, by a case-control study conducted in Japan.
METHODS: The study samples comprised 819 cancer-free controls and 569 cancer cases including lung, head and neck, colorectal, and esophageal cancers.
RESULTS: Compared with the major homozygotes at the Arg326Gln SNP in PTPRJ, a likely homologue of the mouse SCC1 (susceptible to colon cancer), Arg/Gln or Gln/Gln genotypes exhibited an increased colorectal cancer risk with adjusted odds ratios (aOR) of 1.71 (P = 0.021) and 3.74 (P = 4.14 x 10(-4)), respectively. Increased risks were observed with one or more of the combination genotypes of Gln276Pro and Arg326Gln in PTPRJ for most cancer types (aOR range 10.13-55.08, Bonferroni-corrected P = 0.0454-7.20 x 10(-9)). In the PTPN13, major homozygotes of Ile1522Met showed an increased risk for lung squamous cell carcinomas (aOR 1.86), compared to the heterozygotes. Increased risks were observed with at least one of the combination genotypes of the two SNPs, Ile1522Met and Tyr2081Asp, for all but esophageal cancer examined (aOR 3.36-13.75), compared with double heterozygotes. Moreover, these high risks were seen also when all cancer cases were combined (aOR 1.81-6.84).
CONCLUSIONS: PTPRJ and PTPN13 SNPs were found to influence susceptibility to a wide spectrum of cancers. Because allelic frequencies of these SNPs are relatively common in many ethnic groups, these findings are worthy of further study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19672627     DOI: 10.1007/s00432-009-0656-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  Inhibition of Akt and its anti-apoptotic activities by tumor necrosis factor-induced protein kinase C-related kinase 2 (PRK2) cleavage.

Authors:  H Koh; K H Lee; D Kim; S Kim; J W Kim; J Chung
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

Review 2.  Structural and evolutionary relationships among protein tyrosine phosphatase domains.

Authors:  J N Andersen; O H Mortensen; G H Peters; P G Drake; L F Iversen; O H Olsen; P G Jansen; H S Andersen; N K Tonks; N P Møller
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

3.  The protein kinase C-related kinase PRK2 interacts with the protein tyrosine phosphatase PTP-BL via a novel PDZ domain binding motif.

Authors:  C Gross; R Heumann; K S Erdmann
Journal:  FEBS Lett       Date:  2001-05-11       Impact factor: 4.124

Review 4.  Lymphangiogenesis in development and human disease.

Authors:  Kari Alitalo; Tuomas Tammela; Tatiana V Petrova
Journal:  Nature       Date:  2005-12-15       Impact factor: 49.962

5.  Polygenes, risk prediction, and targeted prevention of breast cancer.

Authors:  Paul D P Pharoah; Antonis C Antoniou; Douglas F Easton; Bruce A J Ponder
Journal:  N Engl J Med       Date:  2008-06-26       Impact factor: 91.245

6.  FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS.

Authors:  Erik D Foehr; Gustavo Lorente; Valerie Vincent; Karoly Nikolich; Roman Urfer
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

7.  A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis.

Authors:  Takamune Takahashi; Keiko Takahashi; Raymond L Mernaugh; Nobuo Tsuboi; Hua Liu; Thomas O Daniel
Journal:  Blood       Date:  2006-04-04       Impact factor: 22.113

8.  The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis.

Authors:  Rodolfo Iuliano; Ilaria Le Pera; Carmela Cristofaro; Francesco Baudi; Franco Arturi; Pierlorenzo Pallante; Maria Luisa Martelli; Francesco Trapasso; Lorenzo Chiariotti; Alfredo Fusco
Journal:  Oncogene       Date:  2004-11-04       Impact factor: 9.867

9.  Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers.

Authors:  Claudia A L Ruivenkamp; Tom van Wezel; Carlo Zanon; Alphons P M Stassen; Cestmir Vlcek; Tamás Csikós; Anita M Klous; Nikos Tripodis; Anastassis Perrakis; Lucie Boerrigter; Peter C Groot; Jan Lindeman; Wolter J Mooi; Gerrit A Meijjer; Gert Scholten; Hans Dauwerse; Vaclav Paces; Nico van Zandwijk; Gert Jan B van Ommen; Peter Demant
Journal:  Nat Genet       Date:  2002-06-24       Impact factor: 38.330

Review 10.  Protein tyrosine phosphatases and breast cancer.

Authors:  Gilles Freiss; Françoise Vignon
Journal:  Crit Rev Oncol Hematol       Date:  2004-10       Impact factor: 6.312

View more
  18 in total

1.  Comments on: "Meta-analysis of association between Arg326Gln (rs1503185) and Gln276Pro (rs1566734) polymorphisms of PTPRJ gene and cancer risk".

Authors:  Morteza Gholami; Mahsa M Amoli
Journal:  J Appl Genet       Date:  2019-07-12       Impact factor: 3.240

Review 2.  PTPN13/PTPL1: an important regulator of tumor aggressiveness.

Authors:  Gilles Freiss; Dany Chalbos
Journal:  Anticancer Agents Med Chem       Date:  2011-01       Impact factor: 2.505

Review 3.  Inside the human cancer tyrosine phosphatome.

Authors:  Sofi G Julien; Nadia Dubé; Serge Hardy; Michel L Tremblay
Journal:  Nat Rev Cancer       Date:  2011-01       Impact factor: 60.716

4.  Role of PTPRJ genotype in papillary thyroid carcinoma risk.

Authors:  Rodolfo Iuliano; Dario Palmieri; Huiling He; Angela Iervolino; Eleonora Borbone; Pierlorenzo Pallante; Alessandra Cianflone; Rebecca Nagy; Hansjuerg Alder; George A Calin; Francesco Trapasso; Carla Giordano; Carlo M Croce; Albert de la Chapelle; Alfredo Fusco
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

5.  The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis.

Authors:  K Spring; P Fournier; L Lapointe; C Chabot; J Roussy; S Pommey; J Stagg; I Royal
Journal:  Oncogene       Date:  2015-03-16       Impact factor: 9.867

Review 6.  Update on Management of Squamous Cell Esophageal Cancer.

Authors:  John K Waters; Scott I Reznik
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075

7.  Targeting ERBB receptors shifts their partners and triggers persistent ERK signaling through a novel ERBB/EFNB1 complex.

Authors:  Paola D Vermeer; Paul L Colbert; Bryant G Wieking; Daniel W Vermeer; John H Lee
Journal:  Cancer Res       Date:  2013-06-28       Impact factor: 12.701

8.  SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.

Authors:  Michael S Leibowitz; Raghvendra M Srivastava; Pedro A Andrade Filho; Ann Marie Egloff; Lin Wang; Raja R Seethala; Soldano Ferrone; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2013-01-30       Impact factor: 12.531

9.  Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.

Authors:  E Ellinghaus; M Stanulla; G Richter; D Ellinghaus; G te Kronnie; G Cario; G Cazzaniga; M Horstmann; R Panzer Grümayer; H Cavé; J Trka; O Cinek; A Teigler-Schlegel; A ElSharawy; R Häsler; A Nebel; B Meissner; T Bartram; F Lescai; C Franceschi; M Giordan; P Nürnberg; B Heinzow; M Zimmermann; S Schreiber; M Schrappe; A Franke
Journal:  Leukemia       Date:  2011-11-11       Impact factor: 11.528

10.  EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity.

Authors:  Paul L Colbert; Daniel W Vermeer; Bryant G Wieking; John H Lee; Paola D Vermeer
Journal:  Oncotarget       Date:  2015-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.